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Aims Ischaemic heart failure (IHF) patients have a poor prognosis even with current guideline-derived therapy. Intramyocar-
dial injections of autologous or allogeneic mesenchymal stromal cells might improve cardiac function leading to better
clinical outcome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods The SCIENCE (Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE) consortium has initiated a Horizon
2020 funded multicentre phase II study in six European countries. It is a double-blind, placebo-controlled trial testing
the safety and efficacy of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC) from
healthy donors or placebo in 138 symptomatic IHF patients. Main inclusion criteria are New York Heart Association
class II–III, left ventricular ejection fraction < 45% and N-terminal pro-B-type natriuretic peptide levels > 300 pg/mL.
Patients are randomized in a 2:1 pattern to receive intramyocardial injections of either CSCC_ASC or placebo.
CSCC_ASC and placebo treatments are prepared centralized at Rigshospitalet in 5mL vials as an off-the-shelf
product. Vials are distributed to all clinical partners and stored in nitrogen vapour tanks ready to be used directly
after thawing. A total of 100× 106 CSCC_ASC or placebo are injected directly into viable myocardium in the
infarct border zone using the NOGA XP system (BDS, Cordis, Johnson & Johnson, USA). Primary endpoint is a
centralized core-laboratory assessed change in left ventricular end-systolic volume at 6-month follow-up measured
by echocardiography. The trial started in January 2017, 58 patients were included and treated until July 2018.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion The SCIENCE trial will provide clinical data on efficacy and safety of intramyocardial cell therapy of allogeneic
adipose-derived stromal cells from healthy donors in patients with IHF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Allogeneic therapy • Clinical trial
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Introduction
Regenerative heart failure (HF) therapy might repair damaged heart
muscle tissue.1 Several randomized clinical trials over recent years
found the therapy to be safe but so far not effective, and clin-
ical data remain conflicting. In particular, intramyocardial injec-
tion might reduce patient’s HF symptoms.2–5 Fluoroscopy-guided
intramyocardial injection of bone marrow (BM)-derived progen-
itor cells (CD 133+ cells) in ischaemic refractory cardiomyopa-
thy recently showed improved myocardial perfusion and improved
angina symptoms.6
Mesenchymal stromal cells (MSC) have migratory abilities, can
secrete protective factors, and act as a primary matrix for tis-
sue regeneration.7 Furthermore, MSC possess immunosuppressive
capacities, evade being recognized by a recipient immune system
and can therefore be used as allogeneic therapy without eliciting
an immune response.8,9 The presence of MSC-like cells in different
tissues (adipose tissue, BM, peripheral blood, etc.) indicates their
importance and pre-clinical studies indicate that these cells have
regenerative capacity regardless of tissue origin.7 Adipose-derived
stromal cells (ASC) are very promising since their tissue concen-
tration is 100–300 times higher than the MSC concentration in the
BM.10
Adipose-derived stromal cells are capable of secreting a large
number of angiogenesis-related cytokines, including vascular
endothelial growth factor, granulocyte/macrophage colony stim-
ulating factor and stromal-derived factor-1𝛼.11 They showed
greater pro-angiogenic action compared to BM-MSC and can be
an ideal source for therapeutic angiogenesis in ischaemic disease
in terms of efficacy, accessibility and available tissue amounts.12
The production of allogeneic Cardiology Stem Cell Centre
Adipose-derived Stromal Cells (CSCC_ASC) from healthy donors
was established at Rigshospitalet Copenhagen. CSCC_ASC are
stored in nitrogen vapour containers as an off-the-shelf product
in the hospital ready to be used without any delay. In a phase I
study, this newly developed cryopreserved CSCC_ASC product
from healthy donors was proven safe. Furthermore, feasibility
of the treatment concept was demonstrated.13 The SCIENCE
trial is a phase II, prospective, randomized, European multicentre,
placebo-controlled, double-blind, investigator-initiated clinical trial
with NOGA-guided intramyocardial injection of CSCC_ASC vs.
placebo in patients with chronic ischaemic HF (IHF).
Study design
Study population
The SCIENCE trial has passed the Voluntary Harmonization
process through Clinical Trials Facilitation Groups, European
Medicines Agency. It was approved by the National Competent
Authorities and Ethics Committees in Denmark, Germany, The
Netherlands, Austria, Slovenia and Poland at the end of 2016. The
study is conducted according to Good Clinical Practice and fol-
lows the latest version of the Helsinki Declaration adopted in 2013
at the 64th World Medical Association Assembly, Brazil. The study
is registered in ClinicalTrials.gov (NCT02673164). ..
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.. A total of 138 patients will be enrolled in the SCIENCE study.
Key inclusion criteria are patients aged 30–80 years with chronic
IHF, impaired left ventricular ejection fraction (LVEF < 45% mea-
sured by echocardiography), symptomatic HF [New York Heart
Association (NYHA) class II–III], plasma N-terminal pro-B-type
natriuretic peptide (NT-proBNP) > 300 pg/mL (>35 pmol/L). All
included patients should be on maximal tolerable standard HFmed-
ication and without further treatment options like valvular inter-
vention/surgery or revascularization or implantation of a cardiac
resynchronisation therapy (CRT) device. CRT device implantation
between baseline and the 6-month follow-up exams will lead to
study exclusion due to a possible effect of CRT on the primary end-
point of left ventricular end-systolic volume (LVESV). All inclusion
and exclusion criteria are listed in Table 1.
Overview of the study flow
Patients are screened for trial eligibility, treated and followed
in six European HF centres. Patients with signed informed consent
approved for the study are randomized 2:1 to receive intramy-
ocardial injections of CSCC_ASC or placebo (isotonic saline) in a
double-blind design. Randomization is performed by personnel
at the Cardiology Stem Cell Centre (CSCC) cell-processing unit
before shipment of treatment doses to clinical sites. To assure
blinding of the treatment, the clinical teams, which are responsi-
ble for screening and follow-up of the patients will not participate
in the treatment procedure or be in the catheterization laboratory
during the treatment. Follow-up visits will be 1, 3, 6 and 12months
after treatment for safety and efficacy evaluation. The study algo-
rithm and visit schedule are summarized in Figure 1.
Cell production
CSCC_ASC and placebos (saline) are manufactured at CSCC,
Rigshospitalet, University Hospital Copenhagen. The CSCC holds
a manufacturing authorization (no. 23909) and a tissue establish-
ment authorization (no. 32298) issued and inspected every sec-
ond year by Danish Medicines Agency and Danish Patient Safety
Authority, respectively. The manufacturing procedure is in com-
pliance with the EU Guidelines for Good Manufacturing Practice
(GMP) of Medicinal Products for Human Use (certificate of GMP
compliance no. DK IMP 92217).
The cells are gained from abdominal adipose tissue after lipo-
suction from healthy donors. A donor is eligible only if screening
shows that the donor is healthy and free from risk factors and lab-
oratory tests for relevant infectious disease agents are negative.
Liposuction is performed according to CSCC Standard Operating
Procedures. Approximately 100–150mL lipoaspirate is obtained
from each donor from the abdomen under local anaesthesia by a
plastic surgeon. Animal-free expansion is performed with human
platelet lysate (Cook Regentec) in automated closed bioreactor
systems (Quantum Cell Expansion System, Terumo BCT).14 The
final cell product has had two passages in the bioreactor system.
CSCC_ASC is cryopreserved in CellSeal vials (COOK Regentec)
(110million cells 5mL) in CryoStor CS10 (BioLife Solutions). The
concentration is a little higher than the intended 100× 106 for the
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Inclusion and exclusion criteria of the SCIENCE trial
Inclusion criteria Exclusion criteria
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• 30–80 years of age
• Signed informed consent
• Chronic stable ischaemic heart disease
• Symptomatic HF (NYHA class II–III)
• LVEF ≤ 45% on echocardiography, CT or MRI scan
• Plasma NT-proBNP > 300 pg/mL (> 35 pmol/L)
• Maximal tolerable HF medication unchanged 2months prior to
inclusion
• No option for PCI or CABG
• Patients who have had PCI or CABG within 6months of inclusion
must have a new coronary angiography to rule out early restenosis
• Patients cannot be included until 3months after implantation of a
CRT-D and until 1month after an ICD unit
• HF NYHA class I or IV
• Acute coronary syndrome within 6weeks of inclusion
• Other revascularization treatment within 4months of treatment
• Moderate to severe aortic stenosis (valve area < 1.3 cm2) or valvular
disease with option for surgery or interventional therapy
• Aortic valve replacement with an artificial heart valve. However, a
trans-septal treatment approach can be considered in these patients
• If the patient is expected to be candidate for MitraClip therapy
• Diminished functional capacity for other reasons such as COPD with
FEV1 < 1 L/min, moderate to severe claudication or morbid obesity
• Clinical significant anaemia (Hb < 6mmol/L), leukopenia (leucocytes
< 2×109/L), leukocytosis (leucocytes >14×109/L) or
thrombocytopenia (thrombocytes < 50× 109/L)
• Reduced kidney function (eGFR < 30mL/min)
• Left ventricular thrombus
• Anticoagulation treatment that cannot be paused during cell injections
• Patients with reduced immune response or known anti-HLA
antibodies
• History with malignant disease within 5 years of inclusion or suspected
malignancy – except treated skin cancer other than melanoma
• Pregnant women
• Other experimental treatment within 4weeks of baseline tests
• Life expectancy <1 year
• Participation in another intervention trial
• Known hypersensitivity to DMSO, penicillin and streptomycin
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy with defibrillation; CT, computed tomography;
DMSO, dimethyl sulfoxide; eGFR, estimated glomerular filtration rate; FEV1 , forced expiratory volume in 1 s; Hb, haemoglobin; HF, heart failure; HLA, human leucocyte
antigen; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; NT-proBNP, N-terminal pro-B-type natriuretic
peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
treatment. There is an estimated loss of 10×106 cells during han-
dling of the cells. The cell doses 100× 106 CSCC_ASC is based on
the experience from our previous HF trial where we could see a
dose titrating effect. Patients treated with > 84× 206 cells had the
highest improvement in LVEF and LVESV.4 CSCC_ASC is stored
below −180∘C in nitrogen vapour or dry-storage until clinical use.
Release criteria are sterility, viability (> 80%) and immunopheno-
type [stable positive markers CD90, CD105, CD73 > 80% and
negative markers < 3% CD45, < 5% human leucocyte antigen
(HLA)-DR] and are listed in Table 2. The presence of mycoplasma is
tested from all bioreactor expansions immediately prior to cell har-
vest, and the presence of bacteria, fungi and endotoxins is tested
on the final product, immediately prior to cryopreservation.
Purity, differentiation capacity (adipose, bone, cartilage), and full
phenotyping consistent with ISCT/IFATS standards for the ASC
phenotype as well as genomic stability has been determined dur-
ing manufacturing process development.14–16 Stability studies have
been established, and currently 24-month stability demonstrat-
ing sterility, viability, recovery, ASC immunophenotype, and cell
potency as defined by in vitro cell adherence and proliferation, after
thawing of the final product, has been documented and approved
by competent authorities. Cell delivery is recommended within 1 h
after thawing (5min in sterile water and temperature set at 37∘C). ..
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.. Samples from each batch of CSCC_ASC are stored at CSCC for
future analyses of correlations between cell function and clinical
efficacy as well as for statutory reference samples.
CSCC_ASC vials are shipped in a qualified portable nitrogen
dry-shipper to the trial participating HF units in Europe by World
Courier, in accordance with European rules for Good Distribution
Practices. The randomization code for each delivered vial is avail-
able in a sealed envelope at each site if there is an acute need for
breaking the code in a case of an unexpected serious adverse event.
Safety
Allogeneic treatment
The final CSCC_ASC product is intended for allogeneic treatment.
Each vial will only contain cells from one donor. A total of 6–8
donors will be used to produce the vials for the clinical trial.
There will be no HLA tissue type matching between the donor
and the patients. Allogeneic cell therapy generally poses a risk
for graft-versus-host reaction or host-versus-graft reaction. A
graft-versus-host reaction is considered insignificant from a safety
perspective given the lack of immunologically active cells in the
graft (< 3% CD45 positive cells, <5% HLA-DR cells). MSC not
only inhibit B-cell proliferation, but also the cytokine-induced
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Algorithm of the SCIENCE trial. CCS, Canadian Cardiovascular Society; CSCC_ASC, Cardiology Stem Cell Centre Adipose-derived
Stromal Cells; CT, computed tomography; EF, ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEDV, left ventricular
end-diastolic volume; LVESV, left ventricular end-systolic volume; MRI, magnetic resonance imaging; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; NYHA, New York Heart Association.
proliferation of natural killer (NK) cells. Furthermore, they
prevent cytotoxic activity and cytokine production due to a
sharp down-regulation of surface expression of the activating
NK receptors.8 MSC are also able to suppress proliferation of
stimulated peripheral blood mononuclear cells and to inhibit
differentiation of monocyte-derived dendritic cells. However,
ASC show more potent immunomodulatory effects compared to
BM-MSC, which is related to higher levels of cytokine secretion.9
Furthermore, ASC express only low levels of major histocompat-
ibility complex (MHC) class I (HLA-ABC) and no MHC class II
(HLA-DR) or co-stimulatory molecules, making them less likely to
interact with recipient immune cells.8,9 Although very low levels
of antibody titres toward CSCC_ASC were detected in the phase
I safety study with CSCC_ASC, these titres were not correlated
with clinical events.13
Viral screening
Each donor is tested for human immunodeficiency virus, hepatitis
B and C, syphilis and human T-lymphotropic virus type I/II serology
by serum analysis within 30 days prior to liposuction and on
the day of donation. Donor testing is performed by the Virus
Laboratory, The Blood Bank, Department of Clinical Immunology,
Rigshospitalet, Copenhagen, as authorized by The Danish Patient
Safety Authority. ..
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. Tissue typing and alloantibodies
Tissue typing (low HLA I and II genotyping) is performed of all
donors for the purpose of alloantibody screening in patients after
cell treatment; in The Netherlands it was requested by the Medical
Research Ethics Committee (METC) to perform such analysis
before randomization and allocate accordingly the correct donor
samples at randomization. Blood samples of all patients in this trial
will be stored for later centralized analyses of tissue antibodies
and biomarkers.
NOGA-guided injection
Three-dimensional left ventricular (LV) mapping is performed using
the NOGA XP® system (BDS, Cordis, Johnson & Johnson, USA).
Intramyocardial injection of stem cells using the NOGA plat-
form in patients with ischaemic disease has proven to be safe
and feasible.4,17,18 It reduces the likelihood of systemic toxicity of
the injected substance, resulting in minimal washout, limited expo-
sure of non-target organs and precise placement of the cells to
peri-ischaemic regions (border zone) of the myocardium.
Every patient receives an electromechanical three-dimensional
LV map by point-by-point measurement. Usually >100 veri-
fied points are necessary to obtain a complete LV map. The
system distinguishes between viable [unipolar voltage > 12mV,
bipolar voltage > 2.5mV, local linear shortening (LLS) > 6%],
non-viable-myocardium (unipolar voltage < 6mV, bipolar voltage
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Release criteria of the final Cardiology Stem
Cell Centre Adipose-derived Stromal Cells product
Attribute Acceptance criteria
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number of cells 100–120million cells
ASC viability >80%
Donor serology Negative for
anti-antibody+Ag)
Negative for anti-HCV
Negative for HBsAg
Negative for anti-HBc
Negative for syphilis
Negative for HTLV I/II
Sterility
Bacteria/fungi Negative/negative
Endotoxin level < 70 EU/mL
Mycoplasma Negative
Characterization (immunophenotype) CD90 > 80%
CD105 > 80%
CD73 > 80%
CD45 < 3%
HLA-DR < 5%
ASC, adipose-derived stromal cells; HBsAg, hepatitis B surface antigen; HBc,
hepatitis B core; HCV, hepatitis C virus; HIV, human immunodeficiency virus;
HLA, human leucocyte antigen; HTLV, human T-lymphotropic virus.
< 1.5mV, LLS < 4%] and border zone (unipolar voltage 6–12mV,
bipolar voltage 1.5–2.5mV, LLS 4–6%) around myocardial scar tis-
sue. Cut-off values may vary in the literature, because borders
are not exactly defined.19 Mismatch between unipolar and bipo-
lar signals is observed when the myocardial scar is not transmu-
ral. Border zones are defined after interpretation of all mapping
data and 12–20 injections of 0.3–0.4mL CSCC_ASC (in total
100 Mio cells) or placebo are performed with MYOSTAR® injec-
tion catheters (BDS, Cordis, Johnson & Johnson, USA) with 3D
computer aided navigation precisely in this region. The number
of injections may vary, depending on the scar size and the deci-
sion to split the injected volume to cover all areas of the border
zone, with adequate distance between the injection points. Labo-
ratory measurements of plasma creatine kinase-MB and troponin
will be made before treatment, 6 h and 1 day after to assess possi-
ble myocardial effects. Additionally, echocardiographic assessment
is performed after the procedure to exclude pericardial effusion.
Exemplary images of the NOGA procedure of a 69-year-old patient
with IHF are shown in Figure 2.
Endpoints
Primary endpoint is a centralized core-laboratory assessed change
in LVESV at 6-month follow-up measured in all patients by echocar-
diography.
Secondary endpoints are safety evaluated by development of
donor-specific de novo HLA antibodies and laboratory safety mea-
surements 1, 3 and 6months after treatment. Other endpoints
are changes in LVEF, end-diastolic volume and myocardial mass
at 6-month follow-up measured by echocardiography. Computed ..
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.. tomography (CT) and magnetic resonance imaging (MRI) will be
performed in a subgroup of patients at baseline and 6months after
treatment to evaluate further cardiac function and LVESV.
Other secondary endpoints are changes in NYHA class, Cana-
dian Cardiovascular Society class, Kansas City Cardiomyopathy
Questionnaire, Seattle Angina Questionnaire, 6-minute walking
test, additional echocardiographic measurements, and NT-proBNP
levels. In addition, safety of CSCC_ASC with respect to incidence
and severity of serious adverse events and suspected unrelated
serious adverse events will be evaluated at 12-month follow-up.
A combined endpoint will be assessed of:
i Death, hospitalization for worsening HF, including insertion of
a biventricular pacemaker, hospitalization due to ventricular
tachycardia or fibrillation 1, 2 and 3 years after treatment.
ii Death, hospitalization for any cardiovascular reason, hospital-
ization for worsening HF, including insertion of a biventricular
pacemaker, hospitalization due to ventricular tachycardia or
fibrillation 1, 2 and 3 years after treatment.
Cardiac imaging and analysis
All patients will have echocardiographic assessment at baseline
and in follow-up visits 3, 6 and 12months after treatment to eval-
uate cardiac parameters for primary and secondary endpoints.
Patients with a plasma creatinine <130𝜇mol/L may also undergo
CT scan or MRI (only in patients without implantable cardioverter
defibrillator or pacemaker) to determine the effect of regenerative
therapy on myocardial function at baseline and 6-month follow-up.
Echocardiographic scans will be without contrast and assess
LV end-systolic and end-diastolic volumes, myocardial mass,
LVEF, radial and longitudinal global and segmental strain by
two-dimensional speckle-tracking echocardiography, left atrial vol-
ume, valvular function, and tissue Doppler parameters (e’, s’); this
will be independently and blinded assessed using Philips Intellispace
software. Regarding reproducibility for every individual patient,
all exams will be performed using the same ultrasound machine
preferably operated by the same technician. The inclusion scans
will be investigated before treatment to ensure a proper quality of
imaging before randomization. Endocardial and epicardial borders
will be traced manually in end-diastole and end-systole and the
mitral plane set to define the basal border of the left ventricle.
Study sites electronically transmit all imaging data to a central
server at Netherlands Heart Institute & Lygature/TraIT, Amster-
dam, The Netherlands. All image data are analysed blinded with
the cvi post-processing tool (for CT and MRI: Circle Cardiovas-
cular Imaging, Calgary, Alberta, Canada). Also, NOGA data will be
used to crosscheck and fuse with other imaging modalities to inves-
tigate its value in accurately pointing out the target border zone for
treatment planning using the Cartbox-2 software platform.20,21
Power calculation and statistics
A total of 138 patients, randomized in a 2:1 pattern, with a
maximum dropout rate of 15% before the 6-month follow-up, will
be required to have a statistical power of > 90% to detect an
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Exemplary images of the NOGA procedure of a 69-year-old man with ischaemic heart failure. Three-dimensional left ventricular
mapping performed using the NOGA XP® system. (A) Unipolar voltage (UPV) in right anterior oblique (RAO) (UPV 5–15mV), (B) left anterior
oblique (LAO) (UPV 5–15mV) and (C) in bulls eye projections (UPVwith focus on the border zone 5–8mV) are displayed with margins manually
set to standardized values. (D) Scar definition using bipolar voltage (BPV 0.5–2.5mV) and (E) local linear shortening (LLS, 6–12%). Colour
encoding is displayed at the right upper border of the pictures. White points indicate mapping points and brown dots indicate locations for
injections in the infarction border zone. A mismatch between UPV, BPV and LLS is observed showing maintained electrical viability (UPV,
BPV) in certain areas of the ventricle with no systolic movement (LLS), suggestive of hibernating myocardium; when scar is not transmural,
a mismatch between UPV and BPV is seen, two injections were placed in this specific area; compare posterior area of map in the bulls eye
perspective (viable and contractive) to the anterior-septal region.
absolute change in LVESV of 9.5mL [estimated standard deviation
(SD) 15mL] and 12.7mL (estimated higher SD of 20mL). Change
in LVEF of 3.2% (estimated SD 5%) and of 5.1% (estimated higher
SD of 8%) results in a statistical power of > 90%. An alpha value
of 5% was used in all calculations.
The power calculation of this trial is based on the results of the
MSC-HF trial, a placebo-controlled comparison of intramyocardial
injection of BM-MSC (randomized in a 2:1 pattern) in patients with
IHF.4 In this previous trial, the primary endpoint of LVESVmeasured
with MRI or CT was significantly reduced in the BM-MSC group
(between-group difference of 13.0±12.9mL, P= 0.001). There
was also a significant improvement in LVEF measured with MRI or ..
..
..
..
..
..
..
..
..
..
..
..
..
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. CT (between-group difference of 6.2± 3.8%, P< 0.0001). SD in the
MSC-HF trial was 12.9% for LVESV and 3.8% for LVEF. Since the SD
is higher if echocardiography is employed compared to CT or MRI,
we did the power calculation of this trial with two SDs higher than
in the MSC-HF trial.
Statistical analyses will be performed using SAS 9⋅4 (SAS Insti-
tute Inc., Cary, NC, USA) and SPSS 22 (SPSS Inc., Chicago, IL, USA).
For baseline characteristic comparison and follow-up data between
and within groups, an independent samples t-test and paired t-test
for normally distributed continuous data will be used, respectively.
Mann–Whitney U test will be used for between-group compar-
isons of continuous non-normally distributed data. For baseline
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Stem cell trials with intramyocardial delivery route in patients with ischaemic cardiomyopathy
Author/acronym,
publication dates,
number of patients
(trial design)
Disease and
delivery route
Cell type and dose Methods for efficacy
measurement
Phase, results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FOCUS-HF27: 06/2011,
30 (randomized 2:1)
CICM (EF < 40%),
IM (NOGA)
Autologous BMMC
(30× 106 ± 0 cells) vs.
control
Symptom reduction,
Echo,
SPECT
Phase II, quality of life improved at
6months (P= 0.009), no effect on
cardiac function
TABMMI5: 11/2011,
20 (non-randomized)
CICM (EF ≤ 40%),
IM (TESI)
Autologous BMMC,
CD34+, CD133+
(96± 29×106 cells)
Symptom reduction,
Echo
Phase II, exercise tolerance test
improved (P< 0.01), EF improved
(from 34.9± 4.3 to 41.9± 5.1
at12 months and 42.2± 7.1% at
24months, P= 0.00005)
ALSTER-Stem Cell17:
10/2012, 23
(non-randomized)
3–4weeks after acute
myocardial infarction
(EF < 45%),
IM (NOGA)
Autologous BMMC
(220± 42×106 cells)
MRI Phase II, EF (+7.9± 1.5%, P= 0.001)
at 6months, no effect on scar
volume
POSEIDON2:
12/2012, 30
(randomized,
5 patients each dose
level and cell type)
CICM (EF < 50%),
IM (TESI)
Autologous vs. allogeneic
BM-MSC (20, 100,
200×106 cells)
Symptom reduction,
ESP,
CT
Phase I/II, reduced infarct scar and
end-diastolic diameter (P= 0.001)
at 13months in both groups, no
effect on EF. Symptom reduction in
the autologous cell group. Inverse
dose response to EF and LVESV
MSC-HF4: 07/2015, 60
(randomized 2:1,
double-blind,
placebo-controlled)
CICM (EF < 45%),
IM (NOGA)
Autologous BM-MSC
(77.5± 67.9× 106
cells) vs. placebo
Symptom reduction,
MRI, CT
Phase II, improvement of
LVESV –7.6±13.2mL (P= 0.001),
EF +5.0± 3.8% and stroke volume
+15.6±14.6mL (P< 0.0001) at
6months in the cell group, no
significant symptom reduction
Perin et al.3: 08/2015, 60
(20 randomized
patients each dose, 2:1
vs. control)
CICM (EF < 40%),
IM (NOGA)
Allogeneic BM-MSC (25,
75, 150× 106 cells)
Symptom reduction,
Echo, SPECT
Phase II, HF-MACE reduced at
36months in 150×106 cell group
(P= 0.025)
MyStromalCell18:
11/2017, 10
(non-randomized)
CICM (EF ≤ 45%),
IM (NOGA)
Autologous ASC
(100×106 cells)
Safety Labs, Echo, CT Phase II, tendency towards efficacy
TRIDENT29: 11/2017, 30
(randomized 1:1,
double-blind)
CICM (EF ≤ 50%),
IM (TESI)
Allogeneic BM-MSC (20
or 100× 106 cells)
Symptom reduction, CT,
ESP
Phase II, reduced scar size in both
groups (20×106 P= 0.001,
100×106 P= 0.0002), EF
increased only in 100× 106 cell
group at 12months (+3.7U; IQR
1.1–6.1; P= 0.04)
Kastrup et al.30:
ongoing, 81
(randomized 2:1,
double-blind,
placebo-controlled)
CICM (EF ≤ 45%),
IM (NOGA)
CSCC_ASC (110× 106
cells) vs. placebo
Echo, MRI, CT Phase II
IxCELL-DCM25: 04/2016,
126 (randomized 1:1,
double-blind,
placebo-controlled)
CICM (EF ≤ 35%),
IM (NOGA)
Autologous Ixmyelocel-T
cell product (CD90+
MSC and CD45+,
CD14+ auto-
fluorescent+ activated
macrophages, cell
number not applicable)
Symptom reduction, Echo Primary endpoint (composite
number of deaths, cardiovascular
hospitalizations during 12-month
follow-up) significantly reduced
(P= 0.03), no effect on EF or
LVESV
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Table 3 Continued
Author/acronym,
publication dates,
number of patients
(trial design)
Disease and
delivery route
Cell type and dose Methods for efficacy
measurement
Phase, results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHART-128: 12/2016,
315 (randomized 1:1,
double-blind,
sham-controlled)
CICM (EF ≤ 35%),
IM (C-Cathez™)
Autologous BM-derived
cardiopoietic cells
(>24×106 cells)
Symptom reduction, Echo Hierarchical composite (mortality,
worsening HF, Minnesota Living
with Heart Failure Questionnaire
score, 6-minute walk test, LVESV,
and EF) at 9months neutral
(P= 0.27)
ATHENA26: 02/2017, 31,
(randomized 2:1,
double-blind,
placebo-controlled)
CICM (EF 20–45%),
IM (NOGA)
Autologous ASC (n= 28:
40× 106 and n= 3:
80× 106 cells)
Symptom reduction,
Echo, ESP
VO2 max favoured ASC, fewer
hospitalizations and symptom
reduction in the ASC arm, no
difference in EF and LVESV
ASC, adipose-derived mesenchymal stromal cells; BM, bone marrow; BMMC, bone marrow mononuclear cells; BM-MSC, bone marrow-derived mesenchymal stem cells;
CICM, chronic ischaemic cardiomyopathy; CSCC_ASC, Cardiology Stem Cell Centre Adipose-derived Stromal Cells; CT, computed tomography; Echo, echocardiography; EF,
ejection fraction; ESP, ergospirometry; HF, heart failure; IM, intramyocardial; IQR, interquartile range; LVESV, left ventricular end-systolic volume; MACE, major adverse cardiac
events; MRI, magnetic resonance imaging; VO2, oxygen uptake; SPECT, single photon emission computed tomography.
categorical data, Pearson’s chi-square or Fisher’s exact test will
be used, as appropriate. For follow-up data with more than two
time-points, repeated measures with autoregressive covariance
structure will be used. For nominal repeated data, generalized esti-
mating equations will be used. Fisher’s exact test will be used for
comparison of occurrences of serious adverse events between
groups. A two sided P-value of < 0.05 is considered statistically
significant.
When data are ready for analysis, our statistician will evaluate
missing data, whether the data are missing completely at random
(MCAR) or missing at random (MAR). We will then decide about
handling of missing values.
Current status
Patients will be enrolled during a recruitment phase of 24months.
The trial has been delayed due to different approval processes
in the involved countries and implementation of new regulations
for clinical use of human platelet lysate in the production of stem
cell products. The trial started January 2017 and 58 patients have
been enrolled until July 2018 without safety events. Since minimum
study duration for one patient is 12months, the overall study
duration will be 4 years.
Discussion
The SCIENCE trial is the first European multicentre randomized
phase II trial testing the safety and efficacy of allogeneic CSCC_ASC
from healthy donors or placebo (saline) in 138 patients with symp-
tomatic IHF.
Presently, there is no established and approved regenerative
therapy for patients with heart disease. Our hypothesis is that
cell therapy leads to myocardial regeneration and improvement of
LV parameters. Therefore, the primary endpoint in this phase II ..
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. trial is the centralized core-laboratory assessed change in LVESV
at 6-month follow-up. In the MSC-HF trial, a significant improve-
ment of LVESV and LVEF was observed after 6months.4 LVESV is
considered superior to LVEF when LVEF is low (< 50%) or when
end-systolic volume is high (>100mL).22 Furthermore, LVESV is a
simple yet powerful echocardiographic marker of LV remodelling
that can be measured easily and is an independent predictor of hos-
pitalization for HF in patients with stable coronary heart disease.23
A limitation of the study is that not all patients can have measure-
ments from echocardiography, CT and MRI. However, all patients
receive measurements by echocardiography. Additionally, MRI or
CT scans will be performed in a subgroup of patients without the
possibility of establishing an equal distribution in the treatment
and control group. Not all patients will undergo CT imaging due
to different European radiation protection guidelines in the par-
ticipating centres. Additionally, many HF patients have implantable
cardioverter defibrillator or CRT devices and cannot undergo MRI
imaging.
Cardiac cell therapy employing autologous BM cells applied via
the intracoronary route was previously shown to be safe but not
sufficiently effective.24 Intracoronary delivery may result in many
cells directly lost to the systemic circulation. The transendocardial
delivery route on the other hand, allows precise placement of
cells in the border zone of ischaemic heart regions. Table 3 lists
pertinent trials with cell treatment via the intramyocardial delivery
route.2–5,17,18,25–30 Previous randomized clinical trials with different
cell types suggest that cell-based therapy via the intramyocardial
route of acute and chronic cardiomyopathy is safe, feasible and
possibly effective in improving various surrogate markers of LV
function and symptoms.3–5,17
Discrepancies in previous trials were seen between LV func-
tion improvement and reduction in clinical endpoints. Improvement
in LV function not always goes hand in hand with improvement
of clinical outcome. In the recent IxCELL-DCM trial, mortality
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and cardiovascular hospitalization rates were reduced, without
significant effect on LV function.25 Patients in the ATHENA tri-
als also had fewer hospitalizations and improvement in HF symp-
toms, but no improvement in LVEF.26 Additionally, age and medical
co-morbidities from HF may decrease the number, quality, and
potency of autologous cells. Stratifying cell results by age in the
FOCUS-HF trial showed that younger patients (< 60 years) had
more BMmononuclear cells than older patients (> 60 years), which
may be one of the main reasons for contradictory results in autol-
ogous regenerative therapy.27 The largest trial so far (CHART-1)
with intramyocardial autologous BM cardiopoietic cells demon-
strated safety but the primary endpoint (hierarchical composite
of all-cause mortality, worsening HF, LVESV and ejection fraction)
was neutral.28
Based on the collected experience from previous clinical tri-
als, the lack of an efficient homogeneous cell product prevents
repeatability and dissemination of regenerative therapy. Therefore,
a switch from autologous to allogeneic treatment is necessary to
establish a standardized effective therapy option for patients with
IHF. Allogeneic MSC and ASC have already been used in previ-
ous clinical trials without any side effects.3,13,29 The TRIDENT trial
compared two doses of allogeneic MSC, directly injected intramy-
ocardially in patients with ischaemic cardiomyopathy.29 Although
both cell doses (20 and 100× 106 cells) decreased scar size, only
the 100× 106 dose increased ejection fraction. Improvement of
clinical outcomes and LV parameters following treatment with an
allogeneic cell product of the BM is currently also investigated in a
large phase III trial (DREAM HF-1, NCT02032004).
The Cardiology Stem Cell Centre, Rigshospitalet, University
Hospital Copenhagen, has established new cultivation proto-
cols for the production of allogeneic CSCC_ASC from healthy
donors, which can be stored in nitrogen vapour containers as
an off-the-shelf product ready to be used. In a phase I study, the
newly developed cryopreserved product CSCC_ASC was safe and
demonstrated feasibility and efficacy in 10 patients with IHF.13
Ongoing is a phase II Danish multicentre study with CSCC_ASC in
81 patients with IHF parallel to the SCIENCE trial to provide fur-
ther data on safety and regenerative efficacy. The cell product and
eligibility criteria are similar to the SCIENCE trial.30 The SCIENCE
trial will provide further clinical data from six large European sites
on efficacy and safety of intramyocardial cell therapy of allogeneic
treatment with this newly developed cell product.
To analyse the economic impact of clinical application of regen-
erative stem cell technology for myocardial function at the societal
level and within the health organizations using the present tech-
nology, data related to social aspects of ASC therapy, relating to
resource use and to health-related quality of life, are collected in
the trial, so as to create a solid base for more advanced economic
analyses and approaches.
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